Wheatgrass (Triticum aestivum) has accumulated a growing body of preclinical evidence across multiple health domains, with a smaller but notable clinical trial base. The evidence is strongest for digestive health and lipid support, with additional preclinical support for antioxidant and anti-inflammatory mechanisms.
1. Does Wheatgrass Support Digestive Health in Ulcerative Colitis?
A 2002 double-blind, placebo-controlled RCT published in the Scandinavian Journal of Gastroenterology enrolled 23 patients with active distal ulcerative colitis and assigned them to 100 mL/day of wheatgrass juice or placebo for one month (Ben-Arye et al., 2002). The wheatgrass group experienced a statistically significant reduction in the overall disease activity index and in rectal bleeding severity compared to placebo. This remains the only published double-blind RCT of wheatgrass for any gastrointestinal condition.
First, the sample of 23 participants limits statistical power, and no replication study has been published in the two decades since. Second, the trial used fresh wheatgrass juice — not powder or tablets — making cross-formulation assumptions unsupported. Third, a 2013 systematic review of herbal therapies in inflammatory bowel disease included the Ben-Arye trial and characterized the evidence as promising but preliminary, calling for larger confirmatory studies (Ng et al., 2013). The proposed mechanism involves chlorophyll and flavonoid anti-inflammatory activity in the colonic mucosa, reducing oxidative damage and cytokine-driven tissue destruction.
Evidence quality: Limited (single small RCT; no replication)
2. Does Wheatgrass Reduce Cholesterol and Triglycerides?
A 2017 RCT published in the Journal of Dietary Supplements assigned 60 hyperlipidemic South Asian women to receive 3.5 g/day of Triticum aestivum powder for 10 weeks (Kumar et al., 2017). The wheatgrass group demonstrated reductions in total cholesterol, triglycerides, and Apolipoprotein B levels compared to baseline values. Apolipoprotein B is the primary protein component of LDL particles, making its reduction a cardiovascular-relevant outcome.
First, the study population was narrowly defined — South Asian women with existing hyperlipidemia — and results should not be extrapolated to men, other ethnicities, or normolipidemic individuals. Second, menopausal symptoms were tracked as a secondary outcome and showed non-significant changes, meaning wheatgrass failed to demonstrate benefit for that endpoint. Third, a 2018 systematic review of “superfood” human intervention trials noted that wheatgrass evidence for metabolic syndrome risk factors is sparse relative to other functional foods like green tea or cocoa (van den Driessche et al., 2018). The lipid-modifying mechanism likely involves flavonoid interference with intestinal cholesterol absorption.
Evidence quality: Limited (single RCT in a specific population)
3. Does Wheatgrass Provide Antioxidant Protection?
Antioxidant capacity is wheatgrass’s most consistently documented property at the biochemical level. A 2025 analytical study quantified chlorophyll a at 0.936 mg/mL and chlorophyll b at 0.329 mg/mL in fresh wheatgrass juice, with flavonoid concentrations reaching 7.381 mg/mL and polyphenol concentrations at 2.963 mg/mL (Barbacariu et al., 2025). These concentrations place wheatgrass among more concentrated plant-based polyphenol sources per unit volume.
First, the same 2025 study demonstrated in an animal model that wheatgrass juice supplementation reduced malondialdehyde (a standard lipid peroxidation biomarker) across multiple tissue types and enhanced antioxidant enzyme activities. Second, vitamins C and E present in wheatgrass contribute established radical-scavenging activity — ascorbate in aqueous compartments and tocopherol in lipid membranes. Third, no human RCT has measured changes in oxidative stress biomarkers following wheatgrass supplementation in a placebo-controlled design. The preclinical antioxidant data are strong; the clinical translation gap is the primary limitation.
Evidence quality: Strong preclinical; no human clinical confirmation
4. Does Wheatgrass Support Blood Health?
A 2018 prospective study in Cureus examined wheatgrass in thalassemic children receiving regular blood transfusions (Mutha et al., 2018). The investigators explored whether wheatgrass could reduce transfusion frequency or improve hemoglobin levels. The chlorophyll-hemoglobin structural analogy — both molecules share a porphyrin ring backbone, with magnesium central to chlorophyll and iron central to hemoglobin — has fueled interest in wheatgrass for blood disorders since the 1930s.
First, ingested chlorophyll does not convert to hemoglobin; the biosynthetic pathways are distinct, and structural similarity does not imply metabolic interconversion. Second, clinical data on wheatgrass for thalassemia remain preliminary, with small sample sizes and no large-scale confirmatory trials. Third, a 2017 review of herbal approaches in pancytopenia treatment listed wheatgrass among botanicals with traditional use in blood disorders, while acknowledging limited study quality (Bagwe et al., 2017). Healthy adults should not expect wheatgrass supplementation to meaningfully alter hemoglobin or red blood cell counts.
Evidence quality: Preliminary (small studies, population-specific)
5. Does Wheatgrass Have Anti-Inflammatory Properties?
A 2015 review published in Mini Reviews in Medicinal Chemistry examined wheatgrass’s known bioactive components and their anti-inflammatory mechanisms (Bar-Sela et al., 2015). The review identified chlorophyll, flavonoids, and polyphenols as compounds with documented anti-inflammatory activity in laboratory settings. Flavonoids modulate NF-κB signaling and reduce production of pro-inflammatory cytokines including TNF-α and IL-6 — the same pathways targeted by many pharmaceutical anti-inflammatory agents.
First, the Bar-Sela review explicitly noted that laboratory findings have not translated proportionally into clinical evidence, identifying a “gap between basic and clinical applications.” Second, the ulcerative colitis RCT (Ben-Arye 2002) provides indirect clinical evidence for anti-inflammatory activity, as the disease activity reduction observed is consistent with mucosal anti-inflammatory effects. Third, the 2024 colorectal cancer review confirmed that wheatgrass compounds exhibit anti-inflammatory properties in cell culture and animal models, supporting the biological plausibility of this benefit (Tamraz et al., 2024).
Evidence quality: Strong mechanistic basis; limited direct clinical evidence
6. Does Wheatgrass Protect Against Liver Damage?
A 2014 study published in the Journal of Membrane Biology investigated wheatgrass supplementation in rats with alcohol-induced hepatotoxicity, compounded by heated polyunsaturated fatty acid exposure (Durairaj et al., 2014). Wheatgrass treatment modified membrane fatty acid composition in liver tissue, suggesting a protective effect on cellular membrane integrity under combined oxidative and toxic stress conditions.
First, this evidence comes entirely from an animal model, and translation to human liver outcomes requires clinical trials that have not been conducted. Second, the 2024 Tamraz review noted liver disease among the health areas where wheatgrass shows preclinical promise, while emphasizing the absence of controlled human data. Third, chlorophyll and polyphenol compounds in wheatgrass have documented hepatoprotective mechanisms in multiple plant-based supplements — the effect is biologically plausible but clinically unproven for wheatgrass specifically.
Evidence quality: Preliminary (animal data only; no human trials)
References
- Ben-Arye E et al. (2002). Scandinavian Journal of Gastroenterology. 11989836
- Kumar N et al. (2017). Journal of Dietary Supplements. 28121470
- Barbacariu CA et al. (2025). Animal Reproduction Science. 39965289
- Mutha AS et al. (2018). Cureus. 29755902
- Bar-Sela G et al. (2015). Mini Reviews in Medicinal Chemistry. 26156538
- Tamraz M et al. (2024). International Journal of Molecular Sciences. 38791211
- Durairaj V et al. (2014). Journal of Membrane Biology. 24706101
- Ng SC et al. (2013). Alimentary Pharmacology & Therapeutics. 23981095
- van den Driessche JJ et al. (2018). Food & Function. 29557436
- Bagwe SM et al. (2017). Journal of Complementary & Integrative Medicine. 28195548